Last week, the Federal Circuit held that obviousness-type double patenting trumps patent term adjustment, opening the door for invalidity attacks that to date had been questionable.
In re Cellect was an appeal from a...more
9/6/2023
/ Appeals ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Patent Applications ,
Patent Litigation ,
Patent Ownership ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patent Terms ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Technology
High Stakes: Hatch-Waxman Litigation Comes for Cannabis -
GW Pharma, now a subsidiary of Jazz Pharmaceuticals, is no stranger to patent litigation. It previously found itself on the receiving end of a patent infringement...more
2/3/2023
/ Abbreviated New Drug Application (ANDA) ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Orange Book ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents
Thank you for reading the January 2023 issue of Sterne Kessler's MarkIt to Market® newsletter. This month, we discuss an ongoing trademark dispute between the band OK Go and cereal company Post, how to stay vigilant about...more
1/31/2023
/ Abbreviated New Drug Application (ANDA) ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Declaratory Judgments ,
Domain Name Registration ,
Domain Names ,
False Association ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Orange Book ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Scams ,
Trademark Application ,
Trademark Infringement ,
Trademark Litigation ,
Trademark Registration ,
Trademarks ,
USPTO
IP for Psychedelics: Lessons From Biopharma -
Following hot on the heels of the cannabis industry is the readily emerging psychedelic industry. Indeed, earlier this month, the Psychedelic Bar Association held its first...more
Thank you for reading the September 2022 issue of Sterne Kessler's MarkIt to Market® newsletter. This month, we discuss the how the growing psychedelic industry can learn from the cannabis and biopharma industries regarding...more
Easing Barriers to Medical Marijuana Research May Unlock a New Wave of Innovation; Biopharma Tactics Should Inform Strategic Patent Protection -
While more than two thirds of U.S. states and the District of Columbia have...more
4/1/2022
/ Biopharmaceutical ,
FDA Approval ,
Intellectual Property Protection ,
Marijuana Related Businesses ,
Medical Marijuana ,
Medical Research ,
New Legislation ,
Patent Applications ,
Patent Registration ,
Patents ,
Pharmaceutical Patents
Thank you for reading the March 2022 issue of Sterne Kessler's MarkIt to Market® newsletter. This month, we discuss copyright registration eligibility in relation to non-human authorship and new legislation surrounding...more
3/30/2022
/ Artificial Intelligence ,
Authorship ,
Biopharmaceutical ,
Copyright ,
Copyright Applications ,
Copyright Office ,
Copyright Registration ,
FDA Approval ,
Intellectual Property Protection ,
Marijuana Related Businesses ,
Medical Marijuana ,
Medical Research ,
New Legislation ,
Patent Applications ,
Patent Registration ,
Patents ,
Pharmaceutical Patents ,
Photographs ,
The Copyright Act
In June 2021, the US Patent and Trademark Office (USPTO) published an update to its study of America Invents Act (AIA) trials involving challenges to Orange Book-listed and biologic patents from September 16, 2012, through...more
3/24/2022
/ America Invents Act ,
Biologics ,
Biosimilars ,
Claim Construction ,
Final Written Decisions ,
Hatch-Waxman ,
Orange Book ,
Patent Cancellation ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
USPTO
[co-author: Jamie Dohopolski]
Love it or hate it, ignore the USPTO Patent Trial and Appeal Board (PTAB) at your peril. The introduction of the PTAB as part of the America Invents Act over ten years ago has forever changed...more
3/7/2022
/ §315(e) ,
35 U.S.C. § 285 ,
America Invents Act ,
Attorney's Fees ,
Biologics ,
Biosimilars ,
Biotechnology ,
Chemical Compounds ,
Claim Construction ,
Collateral Estoppel ,
Constitutional Challenges ,
Corporate Counsel ,
Credibility ,
Declaration ,
Depositions ,
Enhanced Damages ,
Estoppel ,
Evidence ,
Ex Partes Reexamination ,
Exceptional Case ,
Expert Testimony ,
Expert Witness ,
Final Written Decisions ,
Hatch-Waxman ,
Injunctive Relief ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Inventors ,
Life Sciences ,
Motion to Amend ,
Obviousness ,
Orange Book ,
Parallel Proceedings ,
Patent Applications ,
Patent Cancellation ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Prosecution History ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Pre-AIA Patents ,
Printed Publications ,
Prior Art ,
Section 112 ,
Section 325(d) ,
Standard Essential Patents ,
Testimony ,
USPTO ,
USPTO Pilot Program ,
Vacated ,
Written Descriptions
An Early Christmas for Arena Pharmaceuticals -
Hot on the heels of acquiring immuno-oncology company Trillium Therapeutics for about $2.22 billion last month, Pfizer was quickly seeking additional promising drug...more
The December 2021 issue of Sterne Kessler's MarkIt to Market® newsletter discusses new enforcement tools courtesy of the Trademark Modernization Act; Pfizer's acquisition of Arena Pharmaceuticals; the latest developments in...more
12/23/2021
/ Acquisitions ,
Brand ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Domain Name Registration ,
Domain Names ,
Ex Partes Reexamination ,
Expungement ,
gTLD ,
ICANN ,
Intellectual Property Protection ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sunrise Periods ,
Trademark Application ,
Trademark Infringement ,
Trademark Modernization Act (TMA) ,
Trademark Registration ,
Trademarks ,
USPTO ,
Websites